Capsule Summaries

Share

Program Content

Activities

  • EMBER 3
    EMBER-3: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After Progression on Prior ET
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2024

    Expires: June 12, 2025

  • KEYNOTE 522 Subgroup Analyses
    KEYNOTE-522: Biomarker and OS Subgroup Analyses of Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in High-Risk Early TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2024

    Expires: June 15, 2025

  • SOLTI VALENTINE
    Phase II SOLTI VALENTINE: Neoadjuvant HER3-DXd ± Letrozole for High-Risk HR+/HER2- EBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2024

    Expires: June 15, 2025

  • PADMA
    PADMA: ET + Palbociclib vs Standard Chemotherapy in High-Risk HR+/HER2- MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2024

    Expires: June 16, 2025

  • ELECTRA and ELEVATE
    ELECTRA and ELEVATE: Elacestrant Combinations for ER+/HER2- Advanced/Metastatic Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2024

    Expires: June 16, 2025

  • neoHIP
    neoHIP: Phase II Trial of Neoadjuvant Pembrolizumab + HER2-Targeted Therapy for HER2-Positive Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2024

    Expires: June 16, 2025

  • DESTINY Breast06 Subgroup Analysis
    DESTINY-Breast06: T-DXd vs Chemotherapy by Pace of Progression on Previous ET in Patients With HR+/HER2-Low or HER2-Ultralow MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2024

    Expires: June 17, 2025

  • RIGHT Choice
    RIGHT Choice: Subgroup Analyses From the Phase II Trial of First-line Ribociclib + ET vs Combination Chemotherapy in Clinically Aggressive HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2024

    Expires: June 17, 2025

  • OlympiA 10 Year Follow Up
    OlympiA: 10-Yr Follow-up With Adjuvant Olaparib in Patients With gBRCA1/2-Mutated HER2-Negative Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2024

    Expires: June 17, 2025

  • GBG 96 GeparDouze
    NSABP B-59/GBG-96-GeparDouze: Phase III Trial of Neoadjuvant CT Plus Atezolizumab Followed by Adjuvant Atezolizumab for Stage II/III TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2024

    Expires: December 16, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation